^
    Back
    Association details:
    Biomarker:RUNX1 mutation
    Cancer:Acute Myelogenous Leukemia
    Regimen: (idarubicin hydrochloride + granulocyte-colony stimulating factor (GCSF) + cytarabine + Epidaza (chidamide) + decitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

    Published date:
    09/03/2021
    Excerpt:
    ...in relapsed/refractory acute myeloid leukemia patients...among the 32 evaluable patients, all 4 with a RUNX1 gene mutation achieved CR after one course of the CDIAG regimen....The CRR in the RUNX1mut group was significantly higher than that in the RUNX1wt group (P = 0.026)...
    DOI:
    10.3389/fonc.2021.726926
    Trial ID:
    NCT03985007